2009 ImmuneThromboPurpuratheTreatParadigm

From GM-RKB
Jump to navigation Jump to search

Subject Headings: Immune Thrombocytopenic Purpura; Treatment; Paradigm; Adults.

Notes

Cited By

Quotes

Abstract

Immune (idiopathic) thrombocytopenic purpura (ITP) is a heterogeneous disease with highly variable severity and an unpredictable response to therapy. This heterogeneity presents a range of problems to the clinician when deciding who should receive pharmacological treatment and when such interventions should be initiated. Treatment guidelines are available but, given the current small amount of data from research and randomized, controlled trials, the guidelines are largely based on expert opinion rather than on evidence. At the moment, it is only recommended that those patients with severe bleeding and/or extremely low platelet counts (<10 × 109/L) definitely require treatment. In all other patients the decision to treat must be made based on a careful evaluation of disease severity, patient characteristics, and the possibility of treatment-related adverse events. This article describes a structured approach to the management of adults with ITP.

References

  • Stasi R, Provan D. Management of immune thrombocytopenic purpura in adults. Mayo Clin Proc 2004;79:504–22. CrossRef,PubMed,Web of Science® Times Cited: 50
  • Dickerhoff R, Von Ruecker A. The clinical course of immune thrombocytopenic purpura in children who did not receive intravenous immunoglobulins or sustained prednisone treatment. J Pediatr 2000;137:629–32. CrossRef,PubMed,CAS,Web of Science® Times Cited: 52
  • Kühne T, Imbach P, Bolton-Maggs PH, Berchtold W, Blanchette V, Buchanan GR, Intercontinental Childhood ITP Study Group. Newly diagnosed idiopathic thrombocytopenic purpura in childhood: an observational study. Lancet 2001;358:2122–5. CrossRef,PubMed,CAS,Web of Science® Times Cited: 80
  • Stasi R, Stipa E, Masi M, et al. Long-term observation of 208 adults with chronic idiopathic thrombocytopenic purpura. Am J Med 1995;98:436–42. CrossRef,PubMed,CAS,Web of Science® Times Cited: 135
  • Portielje J. E., Westendorp R. G., Kluin-Nelemans H. C., Brand A. Morbidity and mortality in adults with idiopathic thrombocytopenic purpura. Blood 2001;97:2549–54. CrossRef,PubMed,CAS,Web of Science® Times Cited: 126
  • McMillan R, Durette C. Long-term outcomes in adults with chronic ITP after splenectomy failure. Blood 2004;104:956–60. CrossRef,PubMed,CAS,Web of Science® Times Cited: 36
  • Neylon A. J., Saunders P. W, Howard M. R., Proctor S.J., Taylor P.R., Northern Region Haematology Group. Clinically significant newly presenting autoimmune thrombocytopenic purpura in adults: a prospective study of a population-based cohort of 245 patients. Br J Haematol 2003;122:966–74. Direct Link: AbstractFull Article (HTML)PDF(167K)References
  • George J. N., Woolf S. H., Raskob G. E., et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood 1996;88:3–40. PubMed,CAS,Web of Science® Times Cited: 700
  • Provan D, Newland A. C., Norfolk D., Bolton-Maggs P., Lilleyman J., Greer I., May A., Murphy M., Ouwelhand W., Watson S. British Committee for Standards in Haematology General Haematology Task Force. Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. Br J Haematol 2003;120:574–96. PubMed,Web of Science® Times Cited: 217
  • Stasi R, Evangelista M. L., Stipa E., Buccisano F., Venditti A., Amadori S. Idiopathic thrombocytopenic purpura: current concepts in pathophysiology and management. Thromb Haemost 2008;99:4–13. PubMed,CAS,Web of Science® Times Cited: 24
  • Bussel J. B., Pham LC. Intravenous treatment with gammaglobulin in adults with immune thrombocytopenic purpura: review of the iterature. Vox Sang 1987;52:206–11. Direct Link: AbstractPDF(525K)References
  • The American Society of Hematology ITP Practice Guideline Panel. Diagnosis and treatment of idiopathic thrombocytopenic purpura: recommendations of the American Society of Hematology. Ann Intern Med 1997;126:319–26. PubMed
  • Culić S. Recombinant factor VIIa for refractive haemorrhage in autoimmune idiopathic thrombocytopenic purpura. Br J Haematol 2003;120:909–10. Direct Link: AbstractFull Article (HTML)PDF(208K)References
  • Barnes C, Blanchette V, Canning P, Carcao M. Recombinant FVIIa in the management of intracerebral haemorrhage in severe thrombocytopenia unresponsive to platelet-enhancing treatment. Transfus Med 2005;15:145–50. Direct Link: AbstractFull Article (HTML)PDF(614K)References
  • Cohen Y. C., Djulbegovic B., Shamai-Lubovitz O., Mozes B. The bleeding risk and natural history of idiopathic thrombocytopenic purpura in patients with persistent low platelet counts. Arch Intern Med 2000;160:1630–8. CrossRef,PubMed,CAS,Web of Science® Times Cited: 83
  • Dolan J. P. Sheppard B. C. DeLoughery T. G. Splenectomy for immune thrombocytopenic purpura: surgery for the 21st century. Am J Hematol 2008;83:93–6. Direct Link: AbstractPDF(171K)References
  • Cheng Y., Wong R. S., Soo Y. O., Chui CH, Lau FY, Chan NP, Wong WS, Cheng G. Initial treatment of immune thrombocytopenic purpura with high-dose dexamethasone. N Engl J Med 2003;349:831–6. CrossRef,PubMed,CAS,Web of Science® Times Cited: 53
  • Mazzucconi M. G., Fazi P., Bernasconi S., et al. Gruppo Italiano Malattie EMatologiche dell’Adulto (GIMEMA) Thrombocytopenia Working Party. Therapy with high-dose dexamethasone (HD-DXM) in previously untreated patients affected by idiopathic thrombocytopenic purpura: a GIMEMA experience. Blood 2007; 109: 1401–7. CrossRef,PubMed,CAS,Web of Science® Times Cited: 24
  • Godeau B., Caulier M. T.]], Decuypere L, Rose C, Schaeffer A, Bierling P. Intravenous immunoglobulin for adults with autoimmune thrombocytopenic purpura: results of a randomised trial comparing 0.5 and 1 g/kg B.W. Br J Haematol 1999;107:716–9. Direct Link: AbstractFull Article (HTML)PDF(105K)References
  • Scaradavou A., Woo B., Woloski B. M., Cunningham-Rundles S, Ettinger LJ, Aledort LM, Bussel JB. Intravenous anti-D treatment of immune thrombocytopenic purpura: experience in 272 patients. Blood 1997;89:2689–700. PubMed,CAS,Web of Science® Times Cited: 156
  • Newman G. C., Novoa MV, Fodero EM, Lesser ML, Woloski BM, Bussel JB. A dose of 75 microg/kg/d of i.v. anti-D increases the platelet count more rapidly and for a longer period of time than 50 microg/kg/d in adults with immune thrombocytopenic purpura. Br J Haematol 2001;112:1076–8. Direct Link: AbstractFull Article (HTML)PDF(205K)References
  • Cooper N. B., Woloski M. R., Fodero E. M., Novoa M., Leber M, Beer JH, Bussel JB. Does treatment with intermittent infusions of intravenous anti-D allow a proportion of adults with recently diagnosed immune thrombocytopenic purpura to avoid splenectomy? Blood 2002;99:1922–* CrossRef,PubMed,CAS,Web of Science® Times Cited: 39
  • Kojouri K., Vesely S. K., Terrell D. R., George J. N.. Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications. Blood 2004;104:2623–34. CrossRef,PubMed,CAS,Web of Science® Times Cited: 90
  • Schilling R.F. Estimating the risk for sepsis after splenectomy in hereditary spherocytosis. Ann Intern Med 1995;122:187–8. PubMed,CAS,Web of Science® Times Cited: 46
  • Taragarona E. M., Espert JJ, Balague C, Sugrañes G, Ayuso C, Lomeña F, Bosch F, Trias M. Residual splenic function after laparoscopic splenectomy: a clinical concern. Arch Surg 1998;133:56–60. CrossRef,PubMed,Web of Science® Times Cited: 45
  • Stasi R., Sarpatwari A., Segal J. B., Osborn J., Evangelista M. L., Cooper N, Provan D, Newland A, Amadori S, Bussel JB. Effects of eradication of Helicobacter pylori infection in patients with immune thrombocytopenic purpura. A systematic review. Blood 2008 Oct 22 (Epub ahead of print). PubMed
  • Laufer D., Ardekian L. Oral Surgery: transexamic acid and blood loss. Br Dent J 1999;186:624. CrossRef
  • Endo Y., Nishimura S., Miura A. Deep-vein thrombosis induced by tranexamic acid in idiopathic thrombocytopenic purpura. JAMA 1988;259:3561–2. CrossRef,PubMed,CAS,Web of Science® Times Cited: 12
  • Arnold D. M., Dentali F., Crowther M. A., Meyer R. M., Cook R. J., Sigouin C., Fraser G. A., Lim W, Kelton JG. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Intern Med 2007;146:25–33. PubMed,Web of Science® Times Cited: 94
  • Kuwana M., Nomura S., Fujimura K., Nagasawa T., Muto Y., Kurata Y, Tanaka S, Ikeda Y. Effect of a single injection of humanized anti-CD154 monoclonal antibody on the platelet-specific autoimmune response in patients with immune thrombocytopenic purpura. Blood 2004;103:1229–36. CrossRef,PubMed,CAS,Web of Science® Times Cited: 31
  • US National Institutes of Health: Rigel Pharmaceuticals. Pilot Study of R935788 for the Treatment of Adult Refractory Immune Thrombocytopenic Purpura (ITP) http://www.clinicaltrials.gov/ct/show/NCT00706342 (accessed on 9 January 2009).
  • Cooper N., Evangelista M. L., Amadori S., Stasi R. Should rituximab be used before or after splenectomy in patients with immune thrombocytopenic purpura? Curr Opin Hematol 2007;14:642–6. CrossRef,PubMed,CAS,Web of Science® Times Cited: 13
  • Kuter D. J., Bussel J. B., Lyons R. M., et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet 2008;371:395–403. CrossRef,PubMed,CAS,Web of Science® Times Cited: 71
  • Bussel J. B., Cheng G., Saleh MN., et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med 2007;357:2237–47. CrossRef,PubMed,CAS,Web of Science® Times Cited: 79
  • Huhn R. D., Fogarty P. F., Nakamura R, et al. High-dose cyclophosphamide with autologous lymphocyte-depleted peripheral blood stem cell (PBSC) support for treatment of refractory chronic autoimmune thrombocytopenia. Blood 2003;101:71–7. CrossRef,PubMed,CAS,Web of Science® Times Cited: 39,


 AuthorvolumeDate ValuetitletypejournaltitleUrldoinoteyear
2009 ImmuneThromboPurpuratheTreatParadigmRorberto StasiImmune Thrombocytopenic Purpura: The Treatment ParadigmEuropean Journal of Haematologyhttp://onlinelibrary.wiley.com/doi/10.1111/j.1600-0609.2008.01208.x/pdf2009
Retrieved from "http://www.gabormelli.com/RKB/index.php?title=2009_ImmuneThromboPurpuratheTreatParadigm&oldid=852201"